Lexeo Therapeutics, Inc. Operating Expenses
Lexeo Therapeutics, Inc. (LXEO) reported Operating Expenses of $28.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Lexeo Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $28.02M, a 8.69% decline year-over-year.
- Lexeo Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $22.33M, a 33.94% decline year-over-year.
- Lexeo Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $23.12M, a 15.58% decline year-over-year.
- Lexeo Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $21.65M, a 31.37% decline year-over-year.
- Lexeo Therapeutics, Inc. operating expenses for fiscal 2025 was $109.26M, a 3.30% increase from fiscal 2024.
- Lexeo Therapeutics, Inc. operating expenses for fiscal 2024 was $105.77M, a 54.37% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. operating expenses for fiscal 2023 was $68.51M, a 12.02% increase from fiscal 2022.
- Lexeo Therapeutics, Inc. operating expenses for fiscal 2022 was $61.16M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.02M 10-Q · filed 2026-08-12 | $50.35M 10-Q · filed 2026-08-12 | $73.47M derived: sum of 3 quarters · filed 2026-08-12 | $95.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $22.33M 10-Q · filed 2026-05-11 | $45.45M derived: sum of 2 quarters · filed 2026-05-11 | $67.10M derived: sum of 3 quarters · filed 2026-05-11 | $97.78M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $23.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $44.76M derived: sum of 2 quarters · filed 2026-03-30 | $75.45M derived: sum of 3 quarters · filed 2026-08-12 | $109.26M 10-K · filed 2026-03-30 |
| 2025-09-30 | $21.65M 10-Q · filed 2025-11-05 | $52.34M derived: sum of 2 quarters · filed 2026-08-12 | $86.14M 10-Q · filed 2025-11-05 | $113.52M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $30.69M 10-Q · filed 2026-08-12 | $64.49M 10-Q · filed 2026-08-12 | $91.88M derived: sum of 3 quarters · filed 2026-08-12 | $123.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $33.80M 10-Q · filed 2026-05-11 | $61.19M derived: sum of 2 quarters · filed 2026-05-11 | $92.73M derived: sum of 3 quarters · filed 2026-05-11 | $116.28M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $27.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $58.92M derived: sum of 2 quarters · filed 2026-03-30 | $82.47M derived: sum of 3 quarters · filed 2026-03-30 | $105.77M 10-K · filed 2026-03-30 |
| 2024-09-30 | $31.54M 10-Q · filed 2025-11-05 | $55.09M derived: sum of 2 quarters · filed 2025-11-05 | $78.38M 10-Q · filed 2025-11-05 | $93.36M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $23.55M 10-Q · filed 2025-08-14 | $46.84M 10-Q · filed 2025-08-14 | $61.81M derived: sum of 3 quarters · filed 2025-08-14 | $82.09M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $23.29M 10-Q · filed 2025-05-12 | $38.27M derived: sum of 2 quarters · filed 2025-05-12 | $58.54M derived: sum of 3 quarters · filed 2025-05-12 | $72.51M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $14.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $35.25M derived: sum of 2 quarters · filed 2025-03-24 | $49.22M derived: sum of 3 quarters · filed 2025-03-24 | $68.51M 10-K · filed 2025-03-24 |
| 2023-09-30 | $20.27M 10-Q · filed 2024-11-13 | $34.25M derived: sum of 2 quarters · filed 2024-11-13 | $53.54M 10-Q · filed 2024-11-13 | $68.73M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $13.97M 10-Q · filed 2024-08-12 | $33.27M 10-Q · filed 2024-08-12 | $48.46M derived: sum of 3 quarters · filed 2024-08-12 | $66.47M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $19.29M 10-Q · filed 2024-05-09 | $34.49M derived: sum of 2 quarters · filed 2024-05-09 | $52.50M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $15.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $33.21M derived: sum of 2 quarters · filed 2024-03-11 | $61.16M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $18.01M 10-Q · filed 2023-12-11 | $45.97M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |